Biodexa Pharmaceuticals (BDRX) Tax Provisions (2016 - 2024)

Biodexa Pharmaceuticals (BDRX) posted Tax Provisions of $160437.7 for Q4 2024, down 65.11% sequentially from $459787.9 in Q4 2022.

Biodexa Pharmaceuticals (BDRX) Tax Provisions (2016 - 2024) Analysis & Trends

Biodexa Pharmaceuticals has reported Tax Provisions for 7 years, with the latest figure at $160437.7 in Q4 2024.

Quarterly Tax Provisions changed N/A year-over-year to $160437.7 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $1.4 million (changed N/A YoY) and the FY2025 annual result came in at $138443.6, down 56.85% from the prior year.
Tax Provisions slipped to $160437.7 in Q4 2024 per BDRX's latest filing, from $459787.9 in the prior quarter.
Over five years, Tax Provisions peaked at $786988.8 in Q4 2020 and troughed at $160437.7 in Q4 2024.
A 4-year average of $431837.7 and a median of $416776.7 in 2022 frame the typical range for Tax Provisions.
The sharpest annual moves came in 2021 and 2022: Tax Provisions plunged 59.58% in 2021, then surged 44.53% in 2022.
Over 4 years, Tax Provisions stood at $786988.8 in 2020, then slumped by 59.58% to $318130.5 in 2021, then soared by 44.53% to $459787.9 in 2022, then slumped by 65.11% to $160437.7 in 2024.
According to Business Quant data, Tax Provisions over the past three periods registered $160437.7, $459787.9, and $416776.7 for Q4 2024, Q4 2022, and Q3 2022 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Taxes (Qtr)
1	Vertex Pharmaceuticals	138.57 Bn	130.72 Bn	2.84 Bn	292.00 Mn
2	Regeneron Pharmaceuticals	85.98 Bn	77.99 Bn	3.93 Bn	230.90 Mn
3	Argenx Se	65.11 Bn	59.92 Bn	1.37 Bn	59.00 Mn
4	Moderna	55.73 Bn	50.59 Bn	52.00 Mn	15.00 Mn
5	BeOne Medicines	41.99 Bn	36.89 Bn	1.53 Bn	75.45 Mn
6	Alnylam Pharmaceuticals	31.64 Bn	28.33 Bn	992.69 Mn	13.31 Mn
7	BioNTech SE	27.70 Bn	9.31 Bn	668.28 Mn	-90.33 Mn
8	Insmed	27.46 Bn	26.30 Bn	358.27 Mn	1.90 Mn
9	Royalty Pharma	27.32 Bn	26.49 Bn	-	-
10	Biodexa Pharmaceuticals	64,183.91	-11.29 Mn	-	-

Download Data